Biological Dynamics, Inc., a company developing and commercializing its proprietary ExoVerita™ platform for early disease detection and other applications, today announced Peter C. Wulff as Chief Financial Officer effective January 1, 2023.
Read MoreBiological Dynamics, an exosome-isolation technology and early disease detection diagnostic company, today announced that it has partnered with both QURE Healthcare and Curta to explore how the company's assay for early detection of pancreatic ductal adenocarcinoma (PDAC) can improve patient outcomes, demonstrate the greatest value to clinicians, and enhance healthcare economics.
Read MoreDiagnostics industry veterans Mike Aicher, Mike Nall, and Mike Russell have joined Biological Dynamics.
Read MoreBiological Dynamics, Inc. announces participation in a series of global events to discuss liquid biopsy industry trends and challenges, and to review new early-stage cancer detection data based on our company’s proprietary platform technology. Events include:
April 5, 2022: Chief Medical Officer Summit 360 – Fireside Chat with Dr. Paul Billings, CEO and Director
April 8 – 13, 2022: AACR (American Association for Cancer Research) Annual Meeting – Lung cancer and Pancreatic cancer data
May 16, 2022: AUA (American Urological Association) Annual Meeting – Bladder cancer data
May 25 – 29, 2022: ISEV (International Society for Extracellular Vesicles) Annual Meeting – Pancreatic, Ovarian, and Bladder cancer data
June 21, 2022: Nephron Liquid Biopsy Innovation Symposium
June 30, 2022: PMWC (Precision Medicine World Conference) – Early-stage cancer data
Biological Dynamics, Inc. announces the publication of its study, Early-Stage Multi-Cancer Detection Using an Extracellular Vesicle Protein-Based Blood Test, published in Nature Communications Medicine. The test correctly identified 71 percent of stage 1 cancers in a combined cohort of pancreatic, ovarian, and bladder cancers with pancreatic stage 1 cancer detection at 96%.
“The results are remarkable and highlight exosomal protein markers as a viable candidate for early-stage cancer detection,” said Scott Lippman, M.D., co-senior author of this report and Director of UC San Diego Moores Cancer Center. “Specifically, pancreatic cancer is notoriously difficult to detect at an early stage, when surgery, the only curative therapy, is possible. Biological Dynamics’ assay is demonstrating the potential for early-stage cancer detection to be included in the standard of care."
Read MoreBiological Dynamics, Inc., a novel multiomic test company focused on detecting diseases at their earliest stages, announced the return of Paul Billings, MD, PhD, FACP, FACMGG to the company as Chief Executive Officer and Director. Previously, Dr. Billings has served in Advisor, Director, and Board Chairman roles before leaving to become Chief Medical Officer and Senior Vice President of Medical Affairs at Natera, Inc.
Read MoreBiological Dynamics, Inc., a multiomics liquid biopsy company focused on detecting cancers at the earliest stages, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its liquid biopsy assay, Exo-PDAC. The test is designed to provide early detection for pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and lethal forms of cancer worldwide.
Read MoreBiological Dynamics is a private molecular diagnostics company located in San Diego. Our proprietary technology offers a novel, fast, and cost-effective lab-on-chip ACE platform that isolates nanoparticles from high conductance physiological solutions.
Our product, the TR(ACE)™ assay, will utilize the platform for monitoring treatment response in oncology. TR(ACE)™ has not been cleared or approved by the U.S. FDA or any foreign regulatory agency.
